Class summary at a glance.

Every drug in the Interleukin-6 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $911.4Mcombined across class
Total Rx claims: 217K44K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Tocilizumab

Brand: ACTEMRA · 144K Part D claims (CY24) · 27K beneficiaries · First FDA approval: 2010-01-08

Brand-only (no generics) 168 plans require PA

Low NADAC$1279.06

→

Avg plan cost$1279.06

Part D spend $585.5M 1× spread, current vs floor

Class share

64%

of class CY24 spend

View profile →

Sarilumab

Brand: KEVZARA · 64K Part D claims (CY24) · 13K beneficiaries · First FDA approval: 2017-05-22

Brand-only (no generics) 113 plans require PA

Low NADAC$2066.48

→

Avg plan cost$2073.15

Part D spend $302.5M 1× spread, current vs floor

Class share

33%

of class CY24 spend

View profile →

Tocilizumab-Aazg

Brand: TYENNE · 10K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 2024-04-15

Brand-only (no generics) 606 plans require PA

Low NADAC$821.71

→

Avg plan cost$821.71

Part D spend $23.4M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.